A pooled analysis of KEYNOTE-001, KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 compared the effects of pembrolizumab versus chemotherapy in patients with PD-L1-positive advanced or metastatic NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.